Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: Charlie Smith who wrote (1690)	2/24/2000 6:36:00 PM
From: MGV	Read Replies (1) \| Respond to of 1754

Charlie, We can talk more later but 1st impressions are that your numbers can't be written off as absurd. The 35% market share for BOL is the one I want to look at. BOL did not get FDA approval for a full range of applications. The market is signalling that the competitors are technology indifferent here. Price is the key for the moment. Without a decided technology advantage over VISX, I think share gains will come with great difficulty. They could do it but its not an easy leap. It is not a pretty picture.